Biocept Announces Clinical Validation and Commercial Launch of its Target Selector(TM) Multi-Gene Liquid Biopsy Panel for Lung Cancer

Stock Information for Biocept Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biocept Inc.

Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
Biocept Reports Third Quarter 2019 Financial Results
Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe
Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019
Biocept's Target Selector(TM) Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting
Biocept's Target Selector(TM) ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
Biocept Announces Issuance of South Korean Patent Covering its Target Selector(TM) Oncogene Mutation Enrichment and Detection Platform
Biocept to Present at Two Investment Conferences in September

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.